Tomas Leanderson appointed new President & CEO for Active Biotech

2008-07-23

Sven Andréasson has been the company's CEO since 1999 and under his leadership Active Biotech has been transformed from a combined vaccine and research company into a company focused on development of novel pharmaceuticals for treatment of cancer and autoimmune diseases.

The Board of Active Biotech AB has today decided to appoint Tomas Leanderson to become the new President & CEO. Tomas Leanderson has been the CSO for Active Biotech since 1999 (www.activebiotech.com).

Sven Andréasson will remain as CEO until September 1st 2008.

For further information please contact;

Mats Arnhög

Chairman of the Board

Telephone: +46 8545037 70

Mobile: +46705 91 50 96

Lund, July 23, 2008

About Active Biotech

Active Biotech AB (OMX NORDIC: ACTI), headquartered in Sweden, is a biotechnology company with R&D focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex® for RA. Please visit www.activebiotech.com for more information.

Active Biotech is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 8:30 a.m. CET on July 23, 2008.